However, whether HuR is a friend or foe in the field of human cancer remains a matter of debate, even if previous evidence shows that targeting the inhibition of HuR presents beneficial effects against glioma [26], prostate cancer [27], breast cancer [28] and pancreatic cancer [29]. Here, ELAVL1 is linked to breast cancer.